doi:10.19982/j.issn.1000-6621.20260388

Abstract

CLC Number:

References 41

[1]	World Health Organization. Global tuberculosis report 2025[R]. Geneva: World Health Organization, 2025.
[2]	World Health Organization. Global tuberculosis report 2024[R]. Geneva: World Health Organization, 2024.
[3]	Maier C, Chesov D, Schaub D, et al. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis[J]. Clin Microbiol Infect, 2023, 29(6): 751-757. doi:10.1016/j.cmi.2023.02.013.
[4]	Conradie F, Diacon A H, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis[J]. N Engl J Med, 2020, 382(10): 893-902. doi:10.1056/NEJMoa1901814.
[5]	Dookie N, Ngema S L, Perumal R, et al. The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives [J]. Clin Microbiol Rev, 2022, 35(4): e0018019. doi:10.1128/cmr.00180-19.
[6]	World Health Organization. WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update[R]. Geneva: World Health Organization, 2016.
[7]	Nunn A J, Phillips P P J, Meredith S K, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis[J]. N Engl J Med, 2019, 380(13): 1201-1213. doi:10.1056/NEJMoa1811867.
[8]	Goodall R L, Meredith S K, Nunn A J, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial[J]. Lancet, 2022, 400(10366): 1858-1868. doi:10.1016/s0140-6736(22)02078-5. pmid: 36368336
[9]	Guglielmetti L, Khan U, Velásquez G E, et al. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis[J]. N Engl J Med, 2025, 392(5): 468-482. doi:10.1056/NEJMoa2400327.
[10]	Nyang’wa B T, Berry C, Kazounis E, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial[J]. Lancet Respir Med, 2024, 12(2): 117-128. doi:10.1016/s2213-2600(23)00389-2.
[11]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update[R]. Geneva: World Health Organization, 2022.
[12]	中华医学会结核病学分会, 耐多药结核病短程治疗中国专家共识编写组. 耐多药结核病短程治疗中国专家共识[J]. 中华结核和呼吸杂志, 2019, 42(1): 5-8. doi:10.3760/cma.j.issn.1001-0939.2019.01.004.
[13]	中国防痨协会, 《中国防痨杂志》编辑委员会, 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所. 耐药结核病全口服短程治疗专家共识[J]. 中国防痨杂志, 2025, 47(7): 830-839. doi:10.19982/j.issn.1000-6621.20250087.
[14]	中华医学会结核病学分会. 中国耐多药/利福平耐药结核病化学治疗指南(2026年版)[J]. 中华结核和呼吸杂志, 2026, 49(6): 623-643. doi:10.3760/cma.j.cn112147-20251104-00674.
[15]	Van Deun A, Maug A K, Salim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis[J]. Am J Respir Crit Care Med, 2010, 182(5): 684-692. doi:10.1164/rccm.201001-0077OC.
[16]	Aung K J, Van Deun A, Declercq E, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients[J]. Int J Tuberc Lung Dis, 2014, 18(10): 1180-1187. doi:10.5588/ijtld.14.0100.
[17]	Falzon D, Schünemann H J, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update[J]. Eur Respir J, 2017, 49(3): 1602308. doi:10.1183/13993003.02308-2016.
[18]	Conradie F, Bagdasaryan T R, Borisov S, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis[J]. N Engl J Med, 2022, 387(9): 810-823. doi:10.1056/NEJMoa2119430.
[19]	Nyang’wa B T, Berry C, Kazounis E, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis[J]. N Engl J Med, 2022, 387(25): 2331-2343. doi:10.1056/NEJMoa2117166.
[20]	Conradie F, Badat T, Poswa A, et al. A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis[J]. N Engl J Med, 2026, 394(24): 2429-2439. doi:10.1056/NEJMoa2503687.
[21]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: Treatment and care[R]. Geneva: World Health Organization, 2025.
[22]	Song Y, Shu W, Pei Y, et al. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China[J]. BMC Med, 2024, 22(1): 401. doi:10.1186/s12916-024-03633-3. pmid: 39300460
[23]	Weng T, Sun F, Li Y, et al. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial[J]. BMC Infect Dis, 2021, 21(1): 183. doi:10.1186/s12879-021-05870-w. pmid: 33596848
[24]	Fu L, Zhang X, Xiong J, et al. Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study[J]. Int J Infect Dis, 2023, 135: 101-108. doi:10.1016/j.ijid.2023.08.001. pmid: 37567554
[25]	Zhang Y, Li Y, Ren Y, et al. Innovating shorter, all-oral, precise, individualized treatment regimen for rifampicin-resistant tuberculosis (INSPIRE TB): study protocol for a pragmatic randomised controlled trial[J]. BMC Infect Dis, 2026, 26(1): 828. doi:10.1186/s12879-026-13017-y.
[26]	Gao J, Gao M, Du J, et al. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT[J]. Trials, 2024, 25(1): 227. doi:10.1186/s13063-024-07946-9. pmid: 38561815
[27]	Sun F, Li Y, Zhang Y, et al. A 6- to 9-months oral regimen for rifampicin-resistant tuberculosis: a randomized open-label noninferiority trial in China[J]. Clin Microbiol Infect, 2026, 32(3): 429-439. doi:10.1016/j.cmi.2025.11.015.
[28]	聂文娟, 孙峰, 王雪钰, 等. 含新药口服短程方案治疗利福平耐药肺结核患者的多中心随机对照临床试验[J]. 中国防痨杂志, 2024, 46 (11): 1313-1319. doi:10.19982/j.issn.1000-6621.20240281.
[29]	中国疾病预防控制中心结核病预防控制中心. 中国结核病防治工作技术指南[M]. 北京: 人民卫生出版社, 2021.
[30]	中国防痨协会, 《中国防痨杂志》编辑委员会, 首都医科大学附属北京胸科医院. 抗结核药物所致QTc间期延长临床监测和管理专家共识[J]. 中国防痨杂志, 2024, 46(1): 8-17. doi:10.19982/j.issn.1000-6621.20230271.
[31]	Wu J, Pan H, Shen L, et al. Assessing the safety of bedaquiline: insight from adverse event reporting system analysis[J]. Front Pharmacol, 2024, 15: 1382441. doi:10.3389/fphar.2024.1382441.
[32]	Motta I, Cusinato M, Ludman A J, et al. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial[J]. Antimicrob Agents Chemother, 2024, 68(7): e0053624. doi:10.1128/aac.00536-24.
[33]	Gerson S L, Kaplan S L, Bruss J B, et al. Hematologic effects of linezolid: summary of clinical experience[J]. Antimicrob Agents Chemother, 2002, 46(8): 2723-2726. doi:10.1128/aac.46.8.2723-2726.2002.
[34]	Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China[J]. Eur Respir J, 2015, 45(1): 161-170. doi:10.1183/09031936.00035114. pmid: 25234807
[35]	Imperial M Z, Nedelman J R, Conradie F, et al. Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis[J]. Clin Infect Dis, 2022, 74(10): 1736-1747. doi:10.1093/cid/ciab699.
[36]	Lifan Z, Sainan B, Feng S, et al. Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis[J]. Int J Tuberc Lung Dis, 2019, 23(12): 1293-1307. doi:10.5588/ijtld.18.0822. pmid: 31931914
[37]	Khan U, Rich M, Franke M F, et al. The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant/Rifampicin-Resistant Tuberculosis Cohort[J]. Clin Infect Dis, 2025, 81(1): 153-158. doi:10.1093/cid/ciae601.
[38]	姚琳, 顾斌斌, 张建平. 抗结核药物所致药物不良反应的临床表现及其处置的研究进展[J]. 抗感染药学, 2023, 20(12): 1229-1234. doi:10.13493/j.issn.1672-7878.2023.12-001.
[39]	阮云洲, 苏伟, 张慧, 等. 我国利福平耐药结核病防治的历史沿革及展望[J]. 中国防痨杂志, 2024, 46(10): 1166-1170. doi:10.19982/j.issn.1000-6621.20240336.
[40]	刘巧, 李忠奇, 竺丽梅, 等. 中国结核病防治服务体系运行现状、问题与对策研究[J]. 中国防痨杂志, 2025, 47(5): 559-568. doi:10.19982/j.issn.1000-6621.20240544.
[41]	梁月新, 李丽媛, 吕柳英, 等. 基于“三位一体”管理体系与传染病全程管理平台的耐药结核病患者主动服务模式应用效果研究[J]. 新发传染病电子杂志, 2026, 11(1): 81-86. doi:10.19871/j.cnki.xfcrbzz.2026.01.013.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 41

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Clinical Tuberculosis Branch of the Chinese Antituberculosis Association, Beijing Chest Hospital, Capital Medical University, Jiangxi Chest Hospital, Changchun Infectious Disease Hospital. Guidelines for the diagnosis and treatment of adult tuberculous meningitis (2026 edition) [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1457-1470.
[2]	Liu Zhenguo, Xing Wu, Ling Jie, Yao Shanhu, Bai Liqiong, Rong Pengfei. Chest imaging combined with artificial intelligence for standardized tuberculosis screening: implementation bottlenecks and optimization strategies [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1471-1479.
[3]	Nie Wenjuan, Zhang Mingyue, Zhang Yungui, Rukeyamu·Abudushalamu , Xu Bing, Jin Long, Liang Ruixia, Wang Furong, Xiong Yu, Cui Junwei, Yi Hengzhong, Zhang Fan, Li Hongzhi, Cao Xuegang, Qiu Lei, Bao Zhijian, Wang Guangming, Zhang Fan, Song Yanan, Zhang Haiqin, Chu Naihui, Cheng Shiming. A 6-month short-course regimen for rifampicin-resistant pulmonary tuberculosis in China: a nationwide multicenter single-arm clinical trial [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1480-1486.
[4]	Jiang Wenxin, Zhang Xiangrong, Tang Peijun, Qin Zhihua, Gao Chunjing, Zhang She, Zhao Xinguo, Zhu Limei, Liu Qiao. Safety analysis of the B-Pa-L/M regimen for rifampicin-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1487-1496.
[5]	Han Yi, Xiao Yu, Kong Weijin, Lin Rong, Lou Jincheng, Xiong Yanjun, Wang Hua, Zhang Yungui. Evaluate the efficacy and safety of the B-Pa-L/M and B-D-L-Lfx/C regimens for the treatment of rifampicin-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1497-1505.
[6]	Huang Pengfei, Xiao Yu, Peng Yi, Xiong Yanjun, Guo Shanshan, Nadila Abulizi, Malipati Aierkenjiang, Wang Hua, Rukeyamu Abudushalamu. Efficacy and safety of 6-month short-course regimen B-Pa-L/M versus 18-month long-course regimen for treating rifampicin-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1506-1514.
[7]	Li Rong, Wang Hua, Zhang Xuejue, Jin Long, Rukeyamu Abudushalamu, Jin Xiuye, Jing Yangfei, Yang Hong, Wu Yanqin, Ren Fei, Nie Wenjuan. Research on the safety of the B-Pa-L/M regimen in the treatment of rifampicin-resistant pulmonary tuberculosis in elderly patients (≥65 Years) [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1515-1522.
[8]	Su Dahong, Li Xiaoli, Yang Bin, Shi Yiheng, Lin Weibing, Miao Tiantian, Zhao Jinfeng, Ma Shang, Huo Fengmin, Wang Guirong. Analysis of drug resistance to bedaquiline, delamanid and linezolid in patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1523-1530.
[9]	Xiang Jingling, Li Rong, Wang Furong, Tong Dongyi, Nie Wenjuan, Pang Yu. Assessment of depressive, anxious, and insomnia symptoms in patients with rifampicin-resistant pulmonary tuberculosis receiving a pretomanid-containing short-course regimen [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1531-1537.
[10]	Wang Zhongjian, Wang Yunji, Niu Yulan, Huang Yan, Kong Jun, Cao Hui, Jiao Fang, Zhang Xia, Zhang Xiangrong. Establishment and application of a physiologically based pharmacokinetic model for pretomanid in the B-Pa-L/M regimen for drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1538-1551.
[11]	Chen Junji, Qi Pingping, Lyu Bangjun, Qin Yuling, Zhong Zaixin, Wang Xilu, Bai Xiangjian, Mo Yi, Shao Jie. Study on the rationality of reading time points and positive criteria for recombinant Mycobacterium tuberculosis fusion protein (EC) skin test: A phase Ⅳ clinical trial [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1552-1560.
[12]	Huang Pengfei, Xiao Yu, Xiong Yanjun, Liang Yaxue, Wang Hua, Zhao Dahai. Impact of nutritional status on early efficacy and adverse drug reactions in patients with drug-resistant pulmonary tuberculosis and construction of a risk scoring model [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1561-1570.
[13]	Liu Xin, Gulijianati Nuermaimaiti, Li Jian, Wang Quan, Lyu Wenjuan, Ding Lina. Clinical efficacy evaluation of probiotics combined with enteral nutrition in the adjuvant treatment of intestinal tuberculosis: a prospective randomized controlled study [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1571-1578.
[14]	Zhang Rui, Hao Yanxing, Song Canlei, Zhu Weitao, Zhu Shiyu. Recurrence influencing factors and active case-finding efficacy analysis among pulmonary tuberculosis patients after successful initial treatment in Jinshan District, Shanghai [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1590-1596.
[15]	Lu Fengyue, Su Biyi, Zhao Wei, Guan Ping, Zhu Jialou, Tan Yaoju. Application value of TB-RNA in early effectiveness evaluation of anti-tuberculosis treatment in patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(10): 1597-1603.